LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Lipid Particles Test Accurately Predicts Cardiovascular Disease

By LabMedica International staff writers
Posted on 07 Apr 2011
Print article
A blood test for low-density lipoprotein (LDL) particles is a more accurate predictor of cardiovascular disease (CVD) events than LDL cholesterol (LDL-C).

A high value proprietary blood test using nuclear magnetic resonance (NMR) technology has demonstrated that the amount of cholesterol per low-density lipoprotein particle (LDL-P) is variable and related in part to particle size, with smaller particles carrying less cholesterol.

Scientists at Wake Forest University School of Medicine, (Winston-Salem, NC, USA), analyzed blood samples obtained at study onset from 5,598 middle-aged men and women free of cardiovascular disease, who participated in a prospective observational study. Participants were followed for a mean of 5.5 years for incident CVD events, including heart attack, coronary heart disease death, angina, stroke, stroke death, or other atherosclerotic or CVD death.

Of 319 total CVD events recorded, 159 occurred in persons with LDL-C and LDL-P numbers that disagreed. The CVD risk of these individuals tracked with LDL-P number regardless of levels of LDL-C and only LDL-P numbers were associated with incidence of CVD. LDL particle levels were measured using the NMR LipoProfile test (LipoScience Inc., Raleigh, NC, USA). LDL-P information can help clinicians personalize and refine LDL treatment decisions, particularly to minimize residual risk in patients with low LDL-C levels. Clinicians historically have used the LDL-C level, the amount of cholesterol carried within LDL particles, to determine how much treatment, if any, a patient needs.

David C. Goff, Jr., MD, PhD, an investigator in the study, said, "In many patients, the standard cholesterol test may not be sufficient to adequately manage LDL levels. Patients who achieve recommended LDL-C goals may not have achieved correspondingly low LDL-P levels and as a consequence, may need further LDL lowering." It is recommended that additional studies should be conducted to estimate the potential value of this information for the prevention of cardiovascular disease in the general population. The study was published online on February 14, 2011, in the Journal of Clinical Lipidology.

Related Links:
Wake Forest University
LipoScience Inc.




Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.